Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.07
$2.04
$1.34
$2.17
$103.79M0.77955,799 shs344,238 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$1.01
$0.96
$0.33
$1.53
$101.36M1.09835,578 shs294,942 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.13
-1.7%
$1.39
$1.04
$4.40
$26.80M1.3167,059 shs60,762 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.74
+2.4%
$1.68
$1.02
$6.23
$96.20M0.99254,189 shs240,730 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HilleVax, Inc. stock logo
HLVX
HilleVax
+0.49%0.00%+0.98%+11.29%+13.11%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
+1.20%-0.98%-16.53%+151.31%+6.34%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
+4.55%-4.17%-20.14%-40.72%+114,999,900.00%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+1.19%-3.95%-7.10%+18.06%-71.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HilleVax, Inc. stock logo
HLVX
HilleVax
1.6117 of 5 stars
1.04.00.00.01.83.31.3
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
1.7368 of 5 stars
3.43.00.00.02.00.00.0
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.2644 of 5 stars
3.55.00.00.02.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HilleVax, Inc. stock logo
HLVX
HilleVax
2.00
Hold$2.00-3.38% Downside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.80
Moderate Buy$5.00395.05% Upside
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
2.00
HoldN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80348.28% Upside

Current Analyst Ratings Breakdown

Latest RNTX, ONCY, HLVX, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
8/13/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$7.00
8/12/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
8/8/2025
HilleVax, Inc. stock logo
HLVX
HilleVax
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/21/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$2.95 per shareN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.04 per shareN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.46 per share2.46$0.13 per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M34.92N/AN/A$3.12 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%N/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%N/A

Latest RNTX, ONCY, HLVX, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.22-$0.28-$0.06-$0.28N/AN/A
8/12/2025Q2 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million
8/8/2025Q2 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.11-$0.05+$0.06-$0.05N/AN/A
8/6/2025Q2 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.14-$0.11+$0.03-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
26.39
26.39
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
2.88
2.88
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
0.86
1.39
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.18
7.06
7.06

Institutional Ownership

CompanyInstitutional Ownership
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
5.10%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
30100.36 million100.26 millionNot Optionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
923.31 million21.87 millionN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable

Recent News About These Companies

What is Lifesci Capital's Forecast for TCRX FY2025 Earnings?
Lifesci Capital Issues Pessimistic Outlook for TCRX Earnings
Wedbush Cuts Earnings Estimates for TScan Therapeutics
HC Wainwright Expects Higher Earnings for TScan Therapeutics
Q3 EPS Estimates for TScan Therapeutics Cut by Wedbush
Research Analysts Set Expectations for TCRX Q3 Earnings
TScan Therapeutics (TCRX) to Release Quarterly Earnings on Monday
TScan Therapeutics Elects New Directors at Annual Meeting

New MarketBeat Followers Over Time

Media Sentiment Over Time

HilleVax stock logo

HilleVax NASDAQ:HLVX

$2.06 0.00 (-0.24%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$1.01 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 +0.00 (+0.50%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.13 -0.02 (-1.74%)
As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.74 +0.04 (+2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$1.75 +0.01 (+0.57%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.